- Live video webcast interactive Q&A with participating companies -
After losing some value lately, a hammer chart pattern has been formed for Palisade Bio, Inc. (PALI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.
Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.
Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of
New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new...
CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for...
Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant...
In-person presentation on Monday, June 13th at 1:45 PM PT...